MOLN

Molecular Partners AG

Phase 2 AI-extracted

MP0533

relapsed/refractory acute myeloid leukemia

Resolved

7days ago

Phase 2 readout · ~ Jun 30, 2026 estimated

What's at stake Phase 2 trial results for MP0533 in relapsed/refractory acute myeloid leukemia are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 15h ago

“Cohort 10 is currently dosing patients and an update on this study is expected in H1 2026.”

Add to calendar Post on X Reddit

Provenance